EviCore Provider Newsroom


Welcome to the new EviCore Providers Newsroom. A home for the latest news for providers, including industry trends, policy changes, program updates, and digital tools and resources.

All articles

You asked, we listened! How we’ve enhanced the portal based on your feedback

January 16, 2026

This year, we’ve focused on making your experience with our portal more efficient, intuitive, and user-friendly. Based on your feedback, we introduced several enhancements, all […] Read more >

Turnaround times shortened for Medicaid and Medicare routine prior authorization requests

January 16, 2026

Effective January 1, 2026, the required turnaround time for routine Medicare and Medicaid prior authorization requests for medical services will drop from 14 to 7 […] Read more >

Program Spotlight: EviCore by Evernorth’s SmartChoice high-tech radiology redirection program

August 6, 2026

EviCore by Evernorth®‘s SmartChoice program is a member outreach and education initiative designed to help patients access cost-effective and convenient in-network services for advanced imaging, […] Read more >

Three tips to streamline your medical oncology and chemotherapy submissions

August 6, 2026

As cancer treatments become increasingly targeted, authorization submissions require more-specific clinical detail. The tips below apply to both physicians documenting in clinical notes and authorization […] Read more >

Save the Date: EviCore by Evernorth provider training and NEW post-acute care portal training 

August 6, 2026

Whether you’re a new user or an experienced user with questions, our free online training sessions can help maximize your experience.  All our training sessions […] Read more >

An improved portal experience: here’s what’s new and what’s on the way

August 6, 2026

If you’ve noticed the portal working a little differently lately, that’s intentional. EviCore by Evernorth® has been rolling out portal updates designed to reduce the […] Read more >

Compassionate use drug spotlight: Daraxonrasib

August 6, 2026

Daraxonrasib is a new oral drug for pancreatic cancer that is not yet approved by the Food and Drug Administration (FDA). However, qualifying patients may […] Read more >

How are we doing?

Please let us know what you think of the Provider Newsroom information and news.

Contact Us